The ongoing debate continues
A message from Editor in Chief Marc B. Garnick, M.D.
Despite little evidence of benefit, most men over age 50 have had a prostate-specific antigen (PSA) test. And since 1992, the prostate cancer mortality rate in the United States has fallen by about 4% a year. But can we credit the falling death rate to PSA screening? Or are other factors, such as better-targeted treatments, playing a part?